Publications by authors named "E A Blomme"

Background: Persistent latent reservoirs of intact HIV-1 proviruses, capable of rebounding despite suppressive antiretroviral therapy (ART), hinder efforts towards an HIV-1 cure. Hence, assays specifically quantifying intact proviruses are crucial to assess the impact of curative interventions. Two recent assays have been utilized in clinical trials: intact proviral DNA assay (IPDA) and quadruplex quantitative PCR (Q4PCR).

View Article and Find Full Text PDF
Article Synopsis
  • Overexpression of BCL-X, an antiapoptotic protein, leads to drug resistance and disease progression in various cancers, making it an attractive target for selective inhibitors.
  • Initial selective BCL-X inhibitors were effective in preclinical models but caused serious cardiovascular toxicity in higher species, prompting the development of safer alternatives using antibody-drug conjugates.
  • The antibody-drug conjugate AM1-15 showed promise by inhibiting tumor growth without causing cardiovascular issues, though it did present other toxicities that were addressed in the modified AM1-AAA, which is now part of the first clinical trial for a selective BCL-X-targeting drug.
View Article and Find Full Text PDF

Background: Reducing the number of active compounds for lifelong HIV treatment is of interest, especially to reduce potential long-term side effects. So far, available data assessing viral control, support the robustness and safety of 2DR (2-drug regimen) ART compared to 3DR. However, further in-depth investigations of the viral reservoirs are mandatory to guarantee long-term safety of these regimens regarding stable intact HIV-1 DNA copies, HIV-1 RNA transcripts and sustained immunological control.

View Article and Find Full Text PDF

The lung is an attractive target organ for inhalation of RNA therapeutics, such as small interfering RNA (siRNA). However, clinical translation of siRNA drugs for application in the lung is hampered by many extra- and intracellular barriers. We previously developed hybrid nanoparticles consisting of an siRNA-loaded nanosized hydrogel (nanogel) core coated with Curosurf®, a clinically used pulmonary surfactant.

View Article and Find Full Text PDF

Toxicogenomic technologies query the genome, transcriptome, proteome, and the epigenome in a variety of toxicological conditions. Due to practical considerations related to the dynamic range of the assays, sensitivity, cost, and technological limitations, transcriptomic approaches are predominantly used in toxicogenomics. Toxicogenomics is being used to understand the mechanisms of toxicity and carcinogenicity, evaluate the translational relevance of toxicological responses from in vivo and in vitro models, and identify predictive biomarkers of disease and exposure.

View Article and Find Full Text PDF